Page 21 of 22
PA8.1-6,PA9.1-2 | Immunopathology & Amyloidosis — Case Study
CLINICAL SCENARIO
A 24-year-old woman presents with a facial rash, swollen joints, frothy urine, and fatigue lasting 3 months. Through a structured case analysis, you will reason through the immunological basis of her illness, interpret her investigations, explain the multisystem pathology, and evaluate the long-term risk of secondary amyloidosis. This case integrates competencies PA8.1–8.6 (hypersensitivity and immunopathology) and PA9.1–9.2 (amyloidosis).
Instructions
Read the clinical scenario carefully. Answer each scaffolded section in sequence — each builds on the previous. Use your SDL notes and recommended references (Robbins Basic Pathology, Chapters 5–6). Cite evidence from the case vignette to support your reasoning. Aim for precision: name the specific immune mechanisms, cells, and mediators involved. After submission, you will peer-review one classmate's response using the provided criteria.
Length: Aim for 1,200–1,800 words total across all six sections. Section 1: ~150 words. Sections 2–5: ~200–250 words each. Section 6: ~300–350 words (integrative synthesis). Quality of mechanistic reasoning matters more than length — avoid padding.
What to Submit
Section 1 — Clinical Reasoning & Differential Diagnosis
Priya, a 24-year-old woman, presents with a 3-month history of fatigue, a butterfly-shaped erythematous rash over her cheeks and nose sparing the nasolabial folds, bilateral painful swollen wrists and fingers, and frothy urine. On examination she has no fever, BP 148/94 mmHg, mild pallor, and non-tender hepatosplenomegaly. Urinalysis shows 3+ protein and red-cell casts.
(a) List three diagnoses in your differential and give one clinching feature for each.
(b) Which single finding — rash morphology, urine sediment, or BP — is most specific for your leading diagnosis, and why?
(c) Which autoantibody panel would you request first, and what result pattern would confirm your diagnosis?
Guidance: Focus on pattern recognition: the combination of photosensitive malar rash + renal involvement + arthritis in a young woman is a classic triad. For (b), distinguish sensitivity from specificity. For (c), recall ANA as a screening test vs. anti-dsDNA/anti-Sm as specific markers; link antibody titres to disease activity.
Section 2 — Immune Mechanism: Loss of Tolerance & Autoantibody Production
Investigations return: ANA titre 1:640 (homogeneous), anti-dsDNA strongly positive, anti-Sm positive, C3 14 mg/dL (↓), C4 4 mg/dL (↓), direct Coombs positive.
(a) Explain the central immunological defect in this disease: why does the immune system target self-antigens? Reference at least two mechanisms of tolerance breakdown.
(b) What is the significance of low complement (C3/C4) in the context of this patient's autoantibodies?
(c) The positive direct Coombs test explains one of her CBC findings — which one, and through what mechanism?
Guidance: Key concepts: central (thymic deletion) and peripheral tolerance (regulatory T cells, anergy, apoptotic debris clearance defects). Low complement reflects consumption by immune-complex activation of the classical pathway — this is evidence of ongoing in-vivo immune-complex deposition, not just circulating antibodies. Coombs positivity = antibody-coated RBCs → extravascular haemolysis.
Section 3 — Hypersensitivity Classification & Tissue Injury Mechanisms
The renal biopsy (light microscopy + immunofluorescence + electron microscopy) is described below:
• LM: Diffuse mesangial and endocapillary hypercellularity; 'wire-loop' glomerular capillary thickening.
• IF: Granular deposits of IgG, IgM, C3, C1q along the glomerular basement membrane and mesangium — a 'full-house' pattern.
• EM: Sub-endothelial and mesangial electron-dense deposits.
(a) Classify the glomerulonephritis using ISN/RPS criteria (Class I–VI) and justify your choice.
(b) Which Gell & Coombs hypersensitivity type best explains the glomerular injury? Describe the sequence: antigen source → immune-complex formation → complement activation → effector cell recruitment → tissue damage.
(c) Why does the 'full-house' IF pattern point specifically to this disease rather than post-streptococcal GN or IgA nephropathy?
Guidance: The LM + IF + EM triad is the classic ISN/RPS Class III/IV descriptor — students should identify diffuse proliferative (Class IV) based on >50% glomeruli involved. Type III hypersensitivity: soluble immune complexes deposit in vessel walls/glomeruli, fix complement, generate C3a/C5a, recruit neutrophils → oxidative burst → GBM damage. Full-house = simultaneous IgG+IgM+IgA+C3+C1q, virtually pathognomonic. Post-strep has only IgG+C3; IgA nephropathy has predominantly IgA.
Section 4 — Multisystem Pathology
Three years later, Priya's disease is incompletely controlled. She has had three flares requiring high-dose steroids. New findings: pericardial rub, pleuritis, painless oral ulcers, and hair thinning. CBC: Hb 8.2 g/dL, WBC 2,800/mm³, platelets 88,000/mm³.
(a) For each new finding (pericarditis, pleuritis, oral ulcers, cytopenias), identify the pathological mechanism — are they all mediated by the same hypersensitivity type, or are different mechanisms involved?
(b) The pancytopenia could result from three distinct mechanisms in this disease. Name all three, with the immune mechanism for each.
(c) A chest X-ray shows a small left pleural effusion. Explain why the protein content and LDH of this effusion will be high.
Guidance: Serositis (pericarditis/pleuritis) = immune-complex deposition + complement activation in serosal membranes. Oral ulcers = vasculitis/immune-complex deposition in mucosal vessels. Cytopenias: (1) autoantibody-mediated destruction (Coombs haemolysis, ITP, autoimmune neutropenia), (2) bone marrow suppression by cytokines, (3) drug effect (steroids/azathioprine). Exudative effusion: damaged inflamed mesothelium leaks protein.
Section 5 — Laboratory Interpretation & Monitoring
Priya's rheumatologist orders a monitoring panel. Results: anti-dsDNA titre rising from 40 IU/mL to 320 IU/mL; C3 falls from 82 to 22 mg/dL; urinary protein:creatinine ratio 3.2 (↑); ESR 110 mm/hr; CRP only mildly elevated.
(a) Anti-dsDNA titre and complement levels are changing in opposite directions. Explain the biochemical reason for this inverse relationship.
(b) In most inflammatory conditions, ESR and CRP rise together. Here ESR is very high but CRP is only mildly elevated. What disease-specific factor explains this dissociation?
(c) If you were to follow just two tests to predict an impending renal flare, which two would you choose and why?
Guidance: Inverse relationship: rising anti-dsDNA generates more immune complexes → classical pathway activation → C3/C4 consumption outpaces hepatic synthesis. ESR/CRP dissociation: Type I interferons (a hallmark of this disease) paradoxically suppress IL-6-driven CRP synthesis in the liver even as the disease is active — a well-known diagnostic trap. Best flare predictors: anti-dsDNA (most sensitive for activity) + C3 or C4 (complement consumption correlates with renal flares).
Section 6 — Integrative Thread: Risk of Secondary AA Amyloidosis
After 8 years of disease with multiple flares and persistent elevation of serum amyloid A (SAA) protein at 240 mg/L (normal <10), Priya develops bilateral leg oedema, heavy proteinuria (nephrotic range), and a serum creatinine that has been creeping up despite adequate immunosuppression.
(a) Define reactive (AA) amyloidosis. What is the precursor protein, what triggers its overproduction, and why does prolonged inflammation predispose to amyloid deposition?
(b) Which organs are most commonly affected in AA amyloidosis, and how does this explain Priya's new symptoms (oedema, proteinuria, rising creatinine)?
(c) How would you distinguish AA amyloidosis from lupus nephritis on a renal biopsy? Name the staining technique and the diagnostic finding, and describe what it looks like under polarised light.
(d) Critically appraise: is controlling the underlying autoimmune disease a valid strategy to prevent or slow amyloid progression? Explain the mechanism.
Guidance: AA amyloidosis: SAA (acute-phase reactant, made in liver under IL-6/IL-1 drive) → proteolytic cleavage → AA fibrils → extracellular deposition (kidney medulla/glomeruli, liver, spleen). Congo red staining → apple-green birefringence under polarised light — the diagnostic gold standard. Controlling inflammation ↓ IL-6/IL-1 → ↓ SAA → ↓ amyloid precursor load; disease-modifying therapy (tocilizumab for AA amyloidosis) validates this mechanism directly.
Grading Rubric — G5 Case Study Marking Rubric (30 points)
| Criterion | Points | Full-marks descriptor |
|---|---|---|
| Clinical Reasoning & Diagnosis (Section 1): Accuracy and specificity of differential, identification of the most specific diagnostic feature, and correct antibody interpretation. | 5 pts | Three well-chosen differentials each with a clinching feature; correctly identifies the most specific finding with a clear sensitivity/specificity rationale; names ANA + anti-dsDNA/anti-Sm as the confirmatory panel with expected pattern. |
| Immune Mechanism — Tolerance Breakdown & Autoantibodies (Section 2): Depth of explanation of tolerance failure, complement consumption logic, and Coombs-haemolysis mechanism. | 5 pts | Names ≥2 specific mechanisms of tolerance breakdown (e.g., defective clearance of apoptotic debris, regulatory T-cell dysfunction); correctly links low C3/C4 to classical pathway consumption by immune complexes; accurately explains Coombs positivity → extravascular haemolysis → anaemia. |
| Hypersensitivity Classification & Renal Biopsy Interpretation (Section 3): Correct ISN/RPS class, Gell & Coombs classification with full mechanistic sequence, and reasoning about full-house immunofluorescence. | 7 pts | Correctly identifies ISN/RPS Class IV (diffuse proliferative) with full justification from LM/IF/EM findings; classifies as Type III hypersensitivity; provides complete mechanistic sequence (immune complexes → complement → C3a/C5a → neutrophil recruitment → oxidative damage to GBM); correctly explains full-house pattern and distinguishes it from post-strep GN and IgA nephropathy. |
| Multisystem Pathology & Lab Monitoring (Sections 4 & 5): Accuracy of pathomechanism for each systemic feature, cytopenia mechanisms, and ESR/CRP dissociation reasoning. | 7 pts | Correctly assigns immune-complex / autoantibody / cytokine mechanism to each systemic feature; names all three mechanisms of pancytopenia (autoantibody destruction, marrow suppression, drug effect); correctly explains exudative effusion; accurately explains inverse anti-dsDNA/complement relationship AND the Type-I interferon-mediated ESR/CRP dissociation; selects anti-dsDNA + C3 (or C4) as the two best flare predictors with sound justification. |
| Integrative Synthesis — Secondary AA Amyloidosis (Section 6): Completeness of amyloidosis pathogenesis, organ targeting explanation, Congo red staining description, and critical appraisal of treatment rationale. | 6 pts | Correctly defines AA amyloidosis with SAA as the precursor, IL-1/IL-6 as the inflammatory drivers, and proteolytic cleavage as the fibril-generating step; names kidney, liver, and spleen as target organs and links renal amyloid deposition to nephrotic syndrome and progressive CKD; correctly describes Congo red staining → apple-green birefringence under polarised light; provides a mechanistic critical appraisal linking immunosuppression → reduced IL-6/IL-1 → reduced SAA → slower amyloid accumulation. |
PEER REVIEW
You will be assigned one classmate's submission to review anonymously. Use the marking rubric above to evaluate each of the five criteria. For each criterion: (1) assign a score from the rating descriptors, (2) write 2–3 sentences of specific feedback identifying what was done well, and (3) write 1–2 sentences suggesting one concrete improvement. Total your scores (max 30). Be constructive and evidence-based — reference specific statements from your peer's response. Peer review contributes to your own grade (see course weightings). Submit your peer review within 48 hours of receiving the assignment.